Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. PART II: Multidisciplinary management

Journal of Surgical Oncology

Volumn 106, Issue 3, 2012, Pages 339-345

  Marsh, Robert De W ^a   Alonzo, Marc ^a   Bajaj, Shailesh ^a   Baker, Marshall ^a   Elton, Eric ^a   Farrell, Thomas A ^a   Gore, Richard M ^a   Hall, Curtis ^a   Nowak, Jan ^a   Roy, Hemant ^a   Shaikh, Arif ^a   Talamonti, Mark S ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

chemotherapy; cholangiocarcinoma; gallbladder cancer; radiation; surgery

Indexed keywords

B RAF KINASE; CA 19-9 ANTIGEN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PHOTOFRIN; SORAFENIB;

ADJUVANT CHEMORADIOTHERAPY; ANTIANGIOGENIC ACTIVITY; BARE METAL STENT; BILE DUCT CARCINOMA; BILIARY PERITONITIS; BILIARY TRACT CANCER; BILIARY TRACT DRAINAGE; BILIARY TRACT HEMORRHAGE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHOLANGITIS; CHOLECYSTECTOMY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER CANCER; GALLBLADDER CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MICROWAVE THERAPY; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PHOTODYNAMIC THERAPY; PNEUMOPERITONEUM; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME;

ABLATION TECHNIQUES; BILIARY TRACT NEOPLASMS; BRACHYTHERAPY; CARCINOMA; COMBINED MODALITY THERAPY; DRAINAGE; ELECTROPORATION; EMBOLIZATION, THERAPEUTIC; ENDOSCOPY, DIGESTIVE SYSTEM; HUMANS; JAUNDICE, OBSTRUCTIVE; LIVER TRANSPLANTATION; LYMPH NODE EXCISION; NEOPLASM METASTASIS; PHOTOCHEMOTHERAPY; PREOPERATIVE CARE; RADIOLOGY, INTERVENTIONAL; RADIOPHARMACEUTICALS; RADIOTHERAPY; STENTS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84864669454     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23027     Document Type: Review

References (80)

1. Perdue DG, Freeman ML, DeSario JA, et al.: Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: A prospective multicenter observational cohort study. J Clin Gastroenterol 2008; 42: 1040-1046.
2. Moss AC, Morris E, Lyden J, et al.: Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007; 19: 1119-1124.
3. Polydorou AA, Chisholm EM, Romano A, et al.: A comparison of right versus left hepatic duct endoprosthesis insertion in malignant hilar biliary obstruction. Endoscopy 1989; 21: 266-271.
4. Deviere J, Baize M, de Toeuf J, et al.: Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988; 34: 95-101.
5. Chang WH, Kortan P, Haber GB,: Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47: 354-362.
6. De Palma GD, Galloro G, Siciliano S, et al.: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: Results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553.
7. Naitoh I, Ohara H, Nakazawa T, et al.: Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. J Gastroenterol Hepatol 2009; 24: 552-557.
8. Freeman ML, Overby C,: Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 2003; 58: 41-49.
9. Yamao K, et al.: Interventional endoscopic ultrasonography. J Gastroenterol Hepatol 2009; 24: 509-519.
10. Ito K, et al.: Current issues regarding endosonography-guided biliary drainage for biliary obstruction. Dig Endosc 2010; 22: S132-S136.
11. Wang Q, Gurusamy KS, Lin H, et al.: Preoperative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2008; CD005444.
12. Hochwald SN, et al.: Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134: 261-266.
13. van der Gaag NA, et al.: Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137.
14. Ortner M-A,: Photodynamic therapy for cholangiocarcinoma: Overview and new developments. Curr Opin Gastroenterol 2009; 25: 472-476.
15. Ortner ME, et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: A randomized prospective study. Gastroenterology 2003; 125: 1355-1363.
16. Zoepf T, et al.: Palliation of nonresectable bile duct cancer: Improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430.
17. Witzigmann H, et al.: Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: Palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006; 244: 230-239.
18. Matull WR, et al.: R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int 2011; 31: 99-107.
19. Wiedmann M, et al.: Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: A phase II pilot study. Cancer 2003; 97: 2783-2790.
20. Nanashima A, et al.: Adjuvant photodynamic therapy for bile duct carcinoma after surgery: A preliminary study. J Gastroenterol 2004; 39: 1095-1101.
21. Ishii H, et al.: Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: Results without stenting. Hepatogastroenterology 2004; 51: 954-957.
22. Singh V, et al.: Endoscopic intraluminal brachytherapy and metal stent in malignant hilar biliary obstruction: A pilot study. Liver Int 2007; 27: 347-352.
23. Weigert N, et al.: Endohyperthermia-experimental evaluation of a new therapeutic approach for treatment of biliary carcinoma. Endoscopy 2000; 32: 306-310.
24. Mantero S, et al.: Hyperthermia in the treatment of cholangiocarcinoma: Development and testing of an endobiliary microwave device. Cardiovasc Intervent Radiol 2003; 26: 379-385.
25. Shih SP, et al.: Gallbladder cancer: The role of laparoscopy and radical resection. Ann Surg 2007; 245: 893-901.
26. Jensen EH, et al.: Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery 2009; 146: 706-711; discussion 711-713.
27. Cho JY, et al.: Laparoscopic approach for suspected early stage gallbladder carcinoma. Arch Surg 2010; 145: 128-133.
28. Hueman MT, Vollmer CM, Jr, Pawlik TM,: Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 2009; 16: 2101-2115.
29. Dixon E, et al.: An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: A 12-year study at a North American Center. Ann Surg 2005; 241: 385-394.
30. Jarnagin WR, et al.: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517; discussion 517-519.
31. DeOliveira ML, et al.: Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762.
32. Ito K, et al.: Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg 2010; 251: 675-681.
33. Miyazaki M, et al.: Combined vascular resection in operative resection for hilar cholangiocarcinoma: Does it work or not? Surgery 2007; 141: 581-588.
34. Nagino M, et al.: Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: An audit of 50 consecutive cases. Ann Surg 2010; 252: 115-123.
35. Rea DJ, et al.: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458; discussion 458-461.
36. Schwartz JJ, et al.: Liver transplantation for cholangiocarcinoma. Transplantation 2009; 88: 295-298.
37. Goldstein RM, et al.: Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993; 166: 768-771; discussion 771-772.
38. Meyer CG, Penn I, James L,: Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000; 69: 1633-1637.
39. Endo I, et al.: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96.
40. Ercolani G, et al.: Intrahepatic cholangiocarcinoma: Primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 2010; 252: 107-114.
41. Hughes MA, et al.: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007; 68: 178-182.
42. Borghero Y, et al.: Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008; 15: 3147-3156.
43. Jarnagin WR, et al.: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 2003; 98: 1689-1700.
44. Gold DG, et al.: Adjuvant therapy for gallbladder carcinoma: The Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 2009; 75: 150-155.
45. Mojica P, Smith D, Ellenhorn J,: Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007; 96: 8-13.
46. Wang SJ, et al.: Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 2008; 26: 2112-2117.
47. Ben-Josef E, et al.: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23: 8739-8747.
48. McMasters KM, et al.: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174: 605-608; discussion 608-609.
49. Nelson JW, et al.: Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009; 73: 148-153.
50. Tse RV, et al.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664.
51. Kopek N, et al.: Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94: 47-52.
52. Goodman KA, et al.: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010; 78: 486-493.
53. Furlan A, et al.: Gallbladder carcinoma update: Multimodality imaging evaluation. Staging and treatment options. Am J Roentgenol 2008; 191: 1440-1447.
54. Kim JH, et al.: Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am J Roentgenol 2011; 196: W205-W209.
55. Martin R, Scoggins C, McMasters K,: Safety and efficacy of microwave ablation of hepatic tumors: A prospective review of a 5-year experience. Ann Surg Oncol 2010; 17: 171-178.
56. Burger I, et al.: Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Intervent Radiol 2005; 16: 353-361.
57. Gusani NJ, et al.: Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience. J Gastrointest Surg 2008; 12: 129-137.
58. Poggi G, et al.: OEM-TACE: A new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009; 32: 1187-1192.
59. Aliberti C, et al.: Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results. Cardiovasc Intervent Radiol 2008; 31: 883-888.
60. Cosimelli M, et al.: Multi-centre phase II clinical trial of Yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331.
61. Overton C, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279. DOI: 10.1097/COC.0b013e31815e4557.
62. Salem R, et al.: Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, survival. J Vasc Intervent Radiol 2005; 16: 1627-1639.
63. Ibrahim SM, et al.: Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres. Cancer 2008; 113: 2119-2128.
64. Hoffmann R-T, Paprottka PM, Schön A, et al.: Transarterial hepatic Yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival. Cardiovasc Intervent Radiol 2011; [Epub ahead of print].
65. Saxena A, et al.: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17: 484-491.
66. Lee EW, Thai S, Kee ST,: Irreversible electroporation: A novel image-guided cancer therapy. Gut Liver 2010; 4: S99-S104.
67. Narayanan G,: Irreversible electroporation for treatment of liver cancer. Gastroenterol Hepatol (N Y) 2011; 7: 313-316.
68. Valle J, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
69. Okusaka T, et al.: Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
70. Sharma A, et al.: Best supportive care compared with chemotherapy for unresectable gall bladder cancer: A randomized controlled study. J Clin Oncol 2010; 28: 4581-4586.
71. Malka D, Trarbach T, Fartoux L, et al.: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with biweekly cetuximab in the first line treatment of advanced biliary cancer: An interim analysis of the BINGO trial. J Clin Oncol 2009; 27: 4520.
72. Gruenberger B, et al.: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study. Lancet Oncol 2010; 11: 1142-1148.
73. Bengala C, et al.: Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial. Br J Cancer 2010; 102: 68-72.
74. Qun W, Tao Y,: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: One case report from China. Hepatogastroenterology 2010; 57: 426-429.
75. Saetta AA, et al.: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004; 445: 179-182.
76. Kim HS, et al.: Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 2010; 41: 1609-1616.
77. Won HS, et al.: Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer 2010; 10: 564.
78. Pignochino Y, et al.: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631.
79. Miller G, et al.: Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 2009; 28: 62.
80. Takada T, et al.: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer 2002; 95: 1685-1695.